SIGA Technologies Q2 revenue, profit drop as contract ends

SIGA Technologies

06/08/2026 21:15

Overview
U.S. infectious disease drugmaker's Q2 revenue and net income fell sharply yr/yr
Lower Q2 results reflect completion of last procurement order under U.S. 19C contract

Outlook
SIGA Technologies did not provide specific guidance or outlook in the press release

Result Drivers
PRODUCT DELIVERIES - Q2 results driven by $24 mln IV TPOXX sales to U.S. stockpile and $13 mln oral TPOXX sales to international customers
CONTRACT COMPLETION - Completion of last procurement order under U.S. 19C contract affected quarterly results

Company press release: ID:nGNXbjJy29

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
 
$12.50 mln
 

Analyst Coverage
The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 8 three months ago

Reuters Recommended Reads
Aug 5 - Emergent BioSolutions swings to Q2 loss on impairment charge; to cut jobs
Aug 5 - BioCryst Pharmaceuticals Q2 revenue rises, lifts 2026 revenue guidance
Aug 5 - Arcus Biosciences Q2 revenue falls sharply on lower license income

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)